Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03975023
Other study ID # Carrick-001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 7, 2019
Est. completion date April 16, 2020

Study information

Verified date January 2021
Source Carrick Institute for Graduate Studies
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Traumatic brain injury (TBI) is a health issue impacting athletes and no clinical treatment protocol, other than rest, is yet established. The efficacy of a treatment protocol relies on objective, physiological measures of brain function and ultimately a quantification of injury severity. The present study aims to assess neurophysiological markers of auditory and visual measures of brain function using the NeuroCatch Platform and eye-tracking technology, respectively. The current gold standard of TBI evaluation, including cognitive and balance assessments, will also be captured.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date April 16, 2020
Est. primary completion date July 11, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 14 Years to 25 Years
Eligibility Inclusion Criteria: - Any sex, 14-25 years old inclusively - Attending the Creative Artists Agency LLC (CAA) hockey camp in July 2019 - Able to understand the informed consent/assent form, study procedures and willing to participate in study NeuroCatch Platform-Specific Inclusion Criteria - Able to remain seated and focused for 6 minutes - Normal hearing capabilities Exclusion Criteria: • Unable to provide informed consent NeuroCatch Platform-Specific Exclusion Criteria - Clinically documented hearing issues (e.g. tinnitus, in-ear hearing problems or punctured ear drum) - In-ear hearing aid or cochlear implant, hearing device - Implanted pacemaker or defibrillator - Metal or plastic implants in skull - Exposed to an investigational drug or device 30 days prior to start in this study, or concurrent or planned use of investigational drug or device during hockey camp (July 7th - 13th 2019) - Not proficient in English - Previous exposure to the NeuroCatch™ Platform audio sequences in the last 6 months - History of seizures - Allergy to rubbing alcohol or EEG gel - Unhealthy scalp (apparent open wounds and/or bruised or weakened skin)

Study Design


Intervention

Device:
NeuroCatch Platform (NCP)
The NCP plays a proprietary 6-minute auditory stimulus sequence of tones and words that elicit involuntary evoked responses in the brain. Tone stimuli elicit N100 and P300 responses, and spoken word pairs elicit N400 responses. The NCP proprietary software identifies the latency and amplitude (timing and size) of three selected ERPs. Latency and amplitude values are reported as empirical (measured) values.

Locations

Country Name City State
United States The Carrick Institute Cape Cañaveral Florida

Sponsors (2)

Lead Sponsor Collaborator
Frederick Carrick, PhD, FACCN HealthTech Connex Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Trends between outcome measures and demographics will be explored Demographics include age, concussion history, and handedness 1 year
Primary ERP response size amplitude in microvolts 1 week
Primary ERP response timing latency in milliseconds 1 week
Primary Eye-tracking: target accuracy distance in millimeters for each eye 1 week
Primary Eye-tracking: speed degrees per second 1 week
Secondary Cognitive tests Cognitive assessments will be captured using Cambridge Brain Sciences battery of neuropsychological tests (composite score) and Highmark Interactive's EQ app 1 year
Secondary Balance Balance measured in seconds as captured by Highmark Interactive's EQ app 1 week
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1